"We Envision Growth Strategies Most Suited
to Your Business"

Europe Prothrombin Complex Concentrate Market to Soar at 10.9% CAGR till 2027; Rising Preference for 3-Factor PCC in Poorer Parts of Europe to Boost the Market

February 03, 2021 | Healthcare

The Europe prothrombin complex concentrate market size is projected to reach USD 398.9 million by 2027 owing to the establishment of stringent guidelines for PCC dosages in warfarin-related bleeding episodes. This information is contained in a recent report by Fortune Business Insights™, titled “Europe Prothrombin Complex Concentrate Market Size, Share & Covid-19 Impact Analysis, By Product (4-factor PCC and 3-factor PCC), By Application (Acquired Coagulation Deficiency and Congenital Coagulation Deficiency and By End User (Hospitals & Ambulatory Surgical Centers, Specialty Clinics, and Others), 2020-2027”. As per the report, the market value stood at USD 174.6 million in 2019 and the market is expected to register a CAGR of 10.9% from 2020 to 2027.


The growth of this market has been minimally affected by the COVID-19 pandemic. Sales of prothrombin complex concentrate (PCC) have remained undisturbed by the pandemic and market players, such as CSL Limited, reported normal revenue earnings amid the coronavirus crisis. However, delays and cancellations of elective surgeries have reduced the demand for bleeding disorder medications marginally.


Takeda Deepens Commitment to Rare Hematology through Real-world Evidence


At the European Association for Haemophilia and Allied Disorders conference, held in February 2020 in the Netherlands, Takeda Pharmaceutical Company presented nine abstracts to demonstrate its commitment to rare hematology. The company has been engaged in gathering empirical evidence to research and develop advanced personalized treatments, including prothrombin complex concentrate, for those living with bleeding complications. The pharmaceutical giant released the main abstract, titled “Incidence and Prevalence of Diagnosed and Undiagnosed Hemophilia A and Hemophilia B in the United Kingdom, Germany, France, Italy, and Spain”, that highlights the need for serving the unmet needs of patients suffering from life-threatening bleeding conditions.


To get a detailed report summary and research scope of this market, click here:


https://www.fortunebusinessinsights.com/europe-prothrombin-complex-concentrate-pcc-market-104721


High Economic Burden of PCC Therapies to Limit Market Growth


One of the major hindrances in the Europe prothrombin complex concentrate market growth is the high costs associated with PCC-based treatments. This factor gains even more significance in the case of hemophilic patients, who end up burning their pockets while getting treated. According to the ‘Cost of Haemophilia in Europe: A Socioeconomic Survey’ (CHESS) study conducted by researchers from the University of Chester and The Haemophilia Society, London, the total annual cost of treating severe hemophilia in France, Germany, Italy, Spain, and the UK (EU5) is estimated be EUR 1.4 billion. The lowest per-patient costs were found to be in the UK, while the highest was observed in Germany, as per the CHESS study. Moreover, average annual indirect costs, mainly in the form of productive work loss, were estimated at approximately EUR 6,000 per patient. Prothrombin complex concentrate therapies, thus, carry a heavy economic burden, which is likely to negatively impact the growth of this market.


Key Players to Engage in Intensive R&D Activities


With the intent to achieve sustainable growth, leading companies in the Europe PCC market are steadily increasing their investments in research and development activities to launch novel prothrombin complex concentrate therapies. Improved R&D capacities will also enable market players to meet the unique medications and treatments necessary to effectively manage chronic, severe bleeding diseases, such as hemophilia. Moreover, the rising prevalence of congenital blood disorders has created immense demand for clotting factor replacement therapy in Europe, spawning multiple opportunities for players in the region.


List of Key Players Profiled in the Europe Prothrombin Complex Concentrate Market Report:



  • Sanquin (Amsterdam, The Netherlands)

  • Octapharma AG (Lachen, Switzerland)

  • CSL Limited (Melbourne, Australia)

  • Takeda Pharmaceutical Company Limited (Tokyo, Japan)

  • Kedrion S.p.A (Lucca, Italy)

  • Grifols, S.A. (Barcelona, Spain) 


Further Report Findings:



  • The hospital pharmacy segment is expected to hold a prominent position in the market owing to the expanding availability of PCC products in hospital-based pharmacies across Europe.

  • Germany is anticipated to lead the Europe prothrombin complex concentrate market share during the forecast period due to the increasing prevalence of complex bleeding disorders in the country. In 2019, the Germany market size stood at USD 46.0 million.


Table of Segmentation











































  ATTRIBUTE



  DETAILS



Study Period



  2016-2027



Base Year



  2019



Forecast Period



  2020-2027



Historical Period



  2016-2018



Unit



  Value (USD million)



Segmentation



By Product Type



  • 4-factor PCC

  • 3-factor PCC



By Application



  • Acquired

  • Congenital



By End User



  • Hospitals & ASCs

  • Specialty Clinics

  • Others



By Geography



  • Europe ( By Product Type, By Application, and By End User )

  • The U.K. (By Product Type, By Application, and By End User)

  • Germany (By Product Type, By Application, and By End User)

  • France (By Product Type, By Application, and By End User)

  • Italy (By Product Type, By Application, and By End User)

  • Spain (By Product Type, By Application, and By End User)

  • Scandinavia (By Product Type, By Application, and By End User)

  • Rest of Europe (By Product Type, By Application, and By End User)


Europe Prothrombin Complex Concentrate (PCC) Market
  • PDF
  • 2019
  • 2016-2018
  • 130

    CHOOSE LICENSE TYPE

  • 3850
    4850
    5850

Our Clients

Itic
UL
GM
Daikin
Lek
We use cookies to enhance your experience. By continuing to visit this site you agree to our use of cookies . Privacy.
X